CECAD Microsite

Research Group "DNA Damage response and Cancer"

Genome maintenance is crucial for the integrity of individual cells and the entire organism. Failure to repair genotoxic lesions leads to an increased mutation frequency and ultimately promotes tumor development. Thus, it is perhaps not surprising that genes involved in DNA damage signaling and DNA repair are among the most frequently altered genes in human cancer. However, defective DNA repair pathways also create molecular liabilities that might be therapeutically exploitable. The research group of Christian Reinhardt aims at discovering novel molecular liabilities using large-scale functional genomics screens. We validate the discoveries derived from our screening platform using biochemical and cell biological approaches, as well as various distinct genetically engineered mouse models of cancer, including models mimicking lung cancer, breast cancer and chronic lymphocytic leukemia. We are closely collaborating with our partners in the clinical departments to actively translate our discoveries into clinical application. The ultimate goal of our work is the development of novel therapeutic approaches for cancer patients.

Lab-News

Alessandro Torgovnick's paper on the Cdkn1aSUPER Mouse as a Tool to Study p53-Mediated Tumor Suppression is published.

Torgovnick et al. create a mouse model, carrying a third copy of Cdkn1a (p21), which shows enhanced cell-cycle arrest capacity and protection against...

Read more

The paper “Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL” with contributions from Arina Riabinska is published.

T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell malignancy. Here we integrated large-scale profiling data of...

Read more

The paper “Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia” with contributions from Anna Schmitt, Ron Jachimowicz and Roberta Castiglione is published.

Deciphering the evolution of cancer cells under therapeutic pressure is a crucial step to understand the mechanisms that lead to treatment resistance....

Read more

Vasiliki Liaki receives SFB-Fellowship

Vasiliki Liaki has been awarded the SFB-Fellowship for Master students in 2017. The Integrated Research Training Group (IRTG) of the SFB 829...

Read more

Fabian Dörr´s paper “Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer” is now online!

The work of Fabian Dörr and colleagues, published in Scientific Reports, indicate that SCLC displays an actionable dependence on ATR/CHK1-mediated...

Read more

Cologne DLBCL Symposium on February 1st, 2018

We have recently developed a strong interest in the biology of DLBCL, particularly ABC-DLBCL. In that regard, Gero Knittel in the lab has generated a...

Read more

We congratulate Anna Schmitt on her scientific poster award!

In the context of the Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Oncology (September 29th - October 3rd, 2017 in...

Read more

Gero Knittel´s paper on ATM-affected CLL is now online!

The work of Gero Knittel and colleagues, published in Nature Communications, provides a preclinical rational for the use of PARP inhibitors in...

Read more

Anna Schmitt´s paper on ATM-deficient pancreatic cancer is now online

In a collaboration, led by Alexander Kleger (Ulm), Anna contributed data, which provide a preclinical rational for the use of PARP inhibitors in...

Read more

We congratule Dr. Arina Riabinska on a very successful PhD Defense!

On July 5th, Dr. Arina Riabinska defended her PhD with the title "The biology and molecular vulnerabilities of ATM-deficient cancers".

Read more